Cresorol - Flavocure Biotech
Alternative Names: ChrysoeriolLatest Information Update: 28 Jun 2024
At a glance
- Originator Flavocure Biotech
- Class Antineoplastics; Flavonoids
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA
- 13 Sep 2022 Cresorol - Flavocure Biotech receives Orphan Drug status for Acute myeloid leukaemia in USA before September 2022 (Flavocure Biotech pipeline, September 2022)
- 03 Sep 2019 Flavocure Biotech has patent protection for Creserol in USA